List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/248016/publications.pdf Version: 2024-02-01

		5126	8627
497	31,545	86	151
papers	citations	h-index	g-index
511	E 1 1	E 1 1	24202
511	511	511	24292
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The influence of comorbid depression and overweight status on peripheral inflammation and cortisol levels. Psychological Medicine, 2022, 52, 3289-3296.	2.7	15
2	A translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings. Molecular Psychiatry, 2022, 27, 81-87.	4.1	16
3	Neurochemical abnormalities in chronic fatigue syndrome: a pilot magnetic resonance spectroscopy study at 7 Tesla. Psychopharmacology, 2022, 239, 163-171.	1.5	5
4	PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression. Evidence-Based Mental Health, 2022, 25, 77-83.	2.2	4
5	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 2022, 27, 1286-1299.	4.1	68
6	The Effect of the 5-HT4 Agonist, Prucalopride, on a Functional Magnetic Resonance Imaging Faces Task in the Healthy Human Brain. Frontiers in Psychiatry, 2022, 13, 859123.	1.3	2
7	The Potential Use of Ebselen in Treatment-Resistant Depression. Pharmaceuticals, 2022, 15, 485.	1.7	6
8	Enhanced Taste Recognition Following Subacute Treatment With The Dopamine D2/D3 Receptor Agonist Pramipexole in Healthy Volunteers. International Journal of Neuropsychopharmacology, 2022, 25, 720-726.	1.0	2
9	An experimental medicine study of the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation in healthy volunteers. Psychopharmacology, 2022, 239, 2635-2645.	1.5	5
10	The effects of statin monotherapy on depressive symptoms: A systematic review and meta-analysis. Journal of Affective Disorders, 2022, 311, 336-343.	2.0	8
11	Translating the promise of 5HT ₄ receptor agonists for the treatment of depression. Psychological Medicine, 2021, 51, 1111-1120.	2.7	26
12	Lithium modulates striatal reward anticipation and prediction error coding in healthy volunteers. Neuropsychopharmacology, 2021, 46, 386-393.	2.8	10
13	Brain Imaging and the Mechanisms of Antidepressant Action. , 2021, , 248-260.		Ο
14	Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis. Journal of Affective Disorders, 2021, 282, 1153-1160.	2.0	33
15	Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2021, 16, e0249409.	1.1	27
16	Trends and variation in antidepressant prescribing in English primary care: a retrospective longitudinal study. BJGP Open, 2021, 5, BJGPO.2021.0020.	0.9	24
17	Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case–control study at 7 T. Translational Psychiatry, 2021, 11, 367.	2.4	16
18	Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies. Frontiers in Psychiatry, 2021, 12, 702617.	1.3	26

#	Article	IF	CITATIONS
19	No evidence for differential gene expression in major depressive disorder PBMCs, but robust evidence of elevated biological ageing. Translational Psychiatry, 2021, 11, 404.	2.4	14
20	A Modest Increase in 11C-PK11195-Positron Emission Tomography TSPO Binding in Depression Is Not Associated With Serum C-Reactive Protein or Body Mass Index. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 716-724.	1.1	10
21	An Experimental Medicine Investigation of the Effects of Subacute Pramipexole Treatment on Emotional Information Processing in Healthy Volunteers. Pharmaceuticals, 2021, 14, 800.	1.7	6
22	Peripheral inflammation is associated with micro-structural and functional connectivity changes in depression-related brain networks. Molecular Psychiatry, 2021, 26, 7346-7354.	4.1	32
23	The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry,the, 2021, 8, 824-835.	3.7	38
24	Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. The Cochrane Library, 2021, 2021, CD011612.	1.5	20
25	Dysconnectivity of a brain functional network was associated with blood inflammatory markers in depression. Brain, Behavior, and Immunity, 2021, 98, 299-309.	2.0	43
26	Effects of various statins on depressive symptoms: is there enough evidence?. Journal of Affective Disorders, 2021, 295, 1093-1094.	2.0	4
27	Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. The Cochrane Library, 2021, 2021, CD011611.	1.5	15
28	DéjÃ-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task. Translational Psychiatry, 2021, 11, 497.	2.4	15
29	When Helping Is Risky: The Behavioral and Neurobiological Trade-off of Social and Risk Preferences. Psychological Science, 2021, 32, 1842-1855.	1.8	5
30	No antidepressant-like acute effects of bright light on emotional information processing in healthy volunteers. Psychopharmacology, 2021, , 1.	1.5	0
31	The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study. Journal of Psychopharmacology, 2021, 35, 1479-1487.	2.0	9
32	A role for 5-HT ₄ receptors in human learning and memory. Psychological Medicine, 2020, 50, 2722-2730.	2.7	36
33	Childhood trauma, HPA axis activity and antidepressant response in patients with depression. Brain, Behavior, and Immunity, 2020, 87, 229-237.	2.0	70
34	Peripheral Blood Cell–Stratified Subgroups of Inflamed Depression. Biological Psychiatry, 2020, 88, 185-196.	0.7	89
35	Whole-blood expression of inflammasome- and glucocorticoid-related mRNAs correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the BIODEP study. Translational Psychiatry, 2020, 10, 232.	2.4	62
36	A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. Psychopharmacology, 2020, 237, 3773-3782.	1.5	41

#	Article	IF	CITATIONS
37	Neural effects of a single dose of fluoxetine on resting-state functional connectivity in adolescent depression. Journal of Psychopharmacology, 2020, 34, 1461-1465.	2.0	1
38	Effect of the NMDA receptor partial agonist, d-cycloserine, on emotional processing and autobiographical memory. Psychological Medicine, 2020, 51, 1-9.	2.7	7
39	A single administration of the antibiotic, minocycline, reduces fear processing and improves implicit learning in healthy volunteers: analysis of the serum metabolome. Translational Psychiatry, 2020, 10, 148.	2.4	14
40	Risk of Depression in the Adolescent and Adult Offspring of Mothers With Perinatal Depression. JAMA Network Open, 2020, 3, e208783.	2.8	57
41	Prescribing for moderate or severe unipolar depression in patients under the long-term care of UK adult mental health services. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532093049.	1.2	6
42	Stress, inflammation and hippocampal subfields in depression: A 7 Tesla MRI Study. Translational Psychiatry, 2020, 10, 78.	2.4	21
43	Treatment-resistant depression and peripheral C-reactive protein. British Journal of Psychiatry, 2019, 214, 11-19.	1.7	241
44	Depression, violence and cortisol awakening response: a 3-year longitudinal study in adolescents. Psychological Medicine, 2019, 49, 997-1004.	2.7	5
45	Electrochemical Detection and Quantification of Lithium Ions in Authentic Human Saliva Using LiMn ₂ O ₄ -Modified Electrodes. ACS Sensors, 2019, 4, 2497-2506.	4.0	32
46	A perspective: from the serotonin hypothesis to cognitive neuropsychological approaches. , 2019, , 95-104.		2
47	Mechanism of Action of ECT. , 2019, , 13-23.		3
48	CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain, 2019, 142, 3243-3264.	3.7	156
49	Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry,the, 2019, 6, 560-561.	3.7	3
50	Optimal dosing of antidepressant drugs – Authors' reply. Lancet Psychiatry,the, 2019, 6, 806-807.	3.7	1
51	A single dose of fluoxetine reduces neural limbic responses to anger in depressed adolescents. Translational Psychiatry, 2019, 9, 30.	2.4	13
52	S120. Neural Effects of Acute Fluoxetine on Emotional Regulation in Depressed Adolescents. Biological Psychiatry, 2019, 85, S343.	0.7	0
53	Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry,the, 2019, 6, 601-609.	3.7	184
54	Antidepressants, withdrawal, and addiction; where are we now?. Journal of Psychopharmacology, 2019, 33, 655-659.	2.0	17

#	Article	IF	CITATIONS
55	Overnight transdermal scopolamine patch administration has no clear effect on cognition and emotional processing in healthy volunteers. Journal of Psychopharmacology, 2019, 33, 255-257.	2.0	6
56	Changes in brain Glx in depressed bipolar patients treated with lamotrigine: A proton MRS study. Journal of Affective Disorders, 2019, 246, 418-421.	2.0	6
57	Subchronic treatment with St John's wort produces a positive shift in emotional processing in healthy volunteers. Journal of Psychopharmacology, 2019, 33, 194-201.	2.0	9
58	The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 84, 152-159.	2.5	28
59	Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychological Medicine, 2018, 48, 1975-1984.	2.7	99
60	Brain glutamate in medication-free depressed patients: a proton MRS study at 7 Tesla. Psychological Medicine, 2018, 48, 1731-1737.	2.7	39
61	3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in service personnel. Lancet Psychiatry,the, 2018, 5, 453-455.	3.7	2
62	How do drugs for psychiatric disorders work?. Epidemiology and Psychiatric Sciences, 2018, 27, 141-142.	1.8	2
63	Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT1A [11C]CUMI-101 PET and Functional MRI Study. Neuropsychopharmacology, 2018, 43, 655-664.	2.8	49
64	Michael Graham Gelder MA, DM Oxon, FRCP, FRCPsych (Hon), FMedSci, DPM. BJPsych Bulletin, 2018, 42, 221-222.	0.7	0
65	A Dissociation of the Acute Effects of Bupropion on Positive Emotional Processing and Reward Processing in Healthy Volunteers. Frontiers in Psychiatry, 2018, 9, 482.	1.3	19
66	The putative lithium-mimetic ebselen reduces impulsivity in rodent models. Journal of Psychopharmacology, 2018, 32, 1018-1026.	2.0	23
67	Predicting Treatment Response in Depression: The Role of Anterior Cingulate Cortex. International Journal of Neuropsychopharmacology, 2018, 21, 988-996.	1.0	70
68	Salivary glutathione in bipolar disorder: A pilot study. Journal of Affective Disorders, 2018, 238, 277-280.	2.0	12
69	Vulnerability to depression is associated with a failure to acquire implicit social appraisals. Cognition and Emotion, 2017, 31, 825-833.	1.2	13
70	How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry,the, 2017, 4, 409-418.	3.7	392
71	Subcortical brain structure and suicidal behaviour in major depressive disorder: a meta-analysis from the ENIGMA-MDD working group. Translational Psychiatry, 2017, 7, e1116-e1116.	2.4	98
72	Melatonin as a treatment for mood disorders: a systematic review. Acta Psychiatrica Scandinavica, 2017, 136, 549-558.	2.2	44

#	Article	IF	CITATIONS
73	Brain glutamate in anorexia nervosa: a magnetic resonance spectroscopy case control study at 7 Tesla. Psychopharmacology, 2017, 234, 421-426.	1.5	23
74	Backing into the future: pharmacological approaches to the management of resistant depression. Psychological Medicine, 2017, 47, 2569-2577.	2.7	29
75	Ultra-High-Field Magnetic Resonance Spectroscopy in Psychiatry. Frontiers in Psychiatry, 2017, 8, 123.	1.3	33
76	Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies. Clinical Epidemiology, 2017, Volume 9, 95-103.	1,5	30
77	Neuroendocrine and Neurochemical Processes in Depression. Psychopathology Review, 2016, a3, 3-15.	0.9	10
78	Altered states: psilocybin for treatment-resistant depression. Lancet Psychiatry,the, 2016, 3, 592-593.	3.7	12
79	Noradrenaline effects on social behaviour, intergroup relations, and moral decisions. Neuroscience and Biobehavioral Reviews, 2016, 66, 54-60.	2.9	50
80	Cognitive mechanisms of diazepam administration: a healthy volunteer model of emotional processing. Psychopharmacology, 2016, 233, 2221-2228.	1.5	14
81	Risks associated with antipsychotic treatment in pregnancy: Comparative cohort studies based on electronic health records. Schizophrenia Research, 2016, 176, 349-356.	1.1	36
82	Effects of typhoid vaccine on inflammation and sleep in healthy participants: a double-blind, placebo-controlled, crossover study. Psychopharmacology, 2016, 233, 3429-3435.	1.5	28
83	Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. Translational Psychiatry, 2016, 6, e957-e957.	2.4	143
84	Fronto-limbic effective connectivity as possible predictor of antidepressant response to SSRI administration. European Neuropsychopharmacology, 2016, 26, 2000-2010.	0.3	59
85	Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. Psychopharmacology, 2016, 233, 2655-2661.	1.5	67
86	Can saliva testing replace blood measurements for health monitoring? Insights from a correlation study of salivary and whole blood glutathione in humans. Analyst, The, 2016, 141, 4707-4712.	1.7	19
87	Effect of short-term escitalopram treatment on neural activation during emotional processing. Journal of Psychopharmacology, 2016, 30, 33-39.	2.0	14
88	Effects of the potential lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance spectroscopy study at 7 tesla. Psychopharmacology, 2016, 233, 1097-1104.	1.5	49
89	Effect of the Putative Lithium Mimetic Ebselen on Brain Myo-Inositol, Sleep, and Emotional Processing in Humans. Neuropsychopharmacology, 2016, 41, 1768-1778.	2.8	85
90	Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Molecular Psychiatry, 2016, 21, 806-812.	4.1	850

#	Article	IF	CITATIONS
91	Frontal Cortex Stimulation Reduces Vigilance to Threat: Implications for the Treatment of Depression and Anxiety. Biological Psychiatry, 2016, 79, 823-830.	0.7	109
92	Acute fluoxetine modulates emotional processing in young adult volunteers. Psychological Medicine, 2015, 45, 2295-2308.	2.7	21
93	What has serotonin to do with depression?. World Psychiatry, 2015, 14, 158-160.	4.8	226
94	Nuevos enfoques para tratar la depresión resistente [translation of "New approaches to treating resistant depression―by Rodolfo Zaratiegui]. BJ Psych Advances, 2015, 21, .	0.5	0
95	Lithium Prescribing during Pregnancy: A UK Primary Care Database Study. PLoS ONE, 2015, 10, e0121024.	1.1	19
96	Neurochemistry of major depression: a study using magnetic resonance spectroscopy. Psychopharmacology, 2015, 232, 501-507.	1.5	80
97	β-Adrenoceptor blockade modulates fusiform gyrus activity to black versus white faces. Psychopharmacology, 2015, 232, 2951-2958.	1.5	10
98	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2015, 29, 459-525.	2.0	528
99	Biological psychiatry–100 words. British Journal of Psychiatry, 2015, 206, 31-31.	1.7	0
100	Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology, 2015, 232, 1793-1801.	1.5	366
101	How Cannabis Causes Paranoia: Using the Intravenous Administration of â^† 9 -Tetrahydrocannabinol (THC) to Identify Key Cognitive Mechanisms Leading to Paranoia. Schizophrenia Bulletin, 2015, 41, 391-399.	2.3	101
102	A "fact of the matter" may not exist in scientific narratives such as serotonin and depression. BMJ, The, 2015, 350, h2501-h2501.	3.0	1
103	Effects of seven-day diazepam administration on resting-state functional connectivity in healthy volunteers: a randomized, double-blind study. Psychopharmacology, 2015, 232, 2139-2147.	1.5	16
104	Decision making in young people at familial risk of depression. Psychological Medicine, 2015, 45, 375-380.	2.7	22
105	Tianeptine in an experimental medicine model of antidepressant action. Journal of Psychopharmacology, 2015, 29, 582-590.	2.0	6
106	New approaches to treating resistant depression. BJ Psych Advances, 2015, 21, 315-323.	0.5	9
107	Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine. Journal of Psychopharmacology, 2015, 29, 1129-1132.	2.0	4
108	Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	42

#	Article	IF	CITATIONS
109	Presynaptic Serotoninergic Regulation of Emotional Processing: A Multimodal Brain Imaging Study. Biological Psychiatry, 2015, 78, 563-571.	0.7	19
110	Short-term escitalopram treatment and hippocampal volume. Psychopharmacology, 2014, 231, 4579-4581.	1.5	7
111	Structural and functional imaging of the hippocampus in young people at familial risk of depression. Psychological Medicine, 2014, 44, 2939-2948.	2.7	33
112	I want to help you, but I am not sure why: Gaze-cuing induces altruistic giving Journal of Experimental Psychology: General, 2014, 143, 763-777.	1.5	29
113	Are You Morally Modified?: The Moral Effects of Widely Used Pharmaceuticals. Philosophy, Psychiatry and Psychology, 2014, 21, 111-125.	0.2	34
114	Discontinuation of antipsychotic medication in pregnancy: A cohort study. Schizophrenia Research, 2014, 159, 218-225.	1.1	51
115	Preliminary evidence that sub-chronic citalopram triggers the re-evaluation of value in intimate partnerships. Social Cognitive and Affective Neuroscience, 2014, 9, 1419-1425.	1.5	10
116	Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. Psychological Medicine, 2014, 44, 2855-2866.	2.7	13
117	Tyrosine-free amino acid mixtures reduce physiologically-evoked release of dopamine in a selective and activity-dependent manner. Journal of Psychopharmacology, 2014, 28, 561-569.	2.0	15
118	Disease, Normality, and Current Pharmacological Moral Modification. Philosophy, Psychiatry and Psychology, 2014, 21, 135-137.	0.2	4
119	When less is more: a functional magnetic resonance imaging study of verbal working memory in remitted depressed patients. Psychological Medicine, 2014, 44, 1197-1203.	2.7	21
120	Effects of short-term varenicline administration on cortisol in healthy, non-smoking adults: a randomized, double-blind, study. Psychopharmacology, 2014, 231, 143-148.	1.5	2
121	Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology, 2014, 231, 2921-2931.	1.5	55
122	Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. Journal of Psychopharmacology, 2014, 28, 536-544.	2.0	148
123	Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy. Psychopharmacology, 2014, 231, 327-332.	1.5	65
124	Folic acid supplementation for prevention of mood disorders in young people at familial risk: A randomised, double blind, placebo controlled trial. Journal of Affective Disorders, 2014, 167, 306-311.	2.0	18
125	Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. Psychopharmacology, 2014, 231, 4323-4335.	1.5	44
126	Effect of interferon-α on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study. Psychological Medicine, 2014, 44, 789-795.	2.7	23

#	Article	IF	CITATIONS
127	Authors' response. Psychiatric Bulletin (2014), 2014, 38, 88-88.	0.4	Ο
128	Amine Depletors. , 2014, , 1-4.		0
129	Early markers of cognitive enhancement: developing an implicit measure of cognitive performance. Psychopharmacology, 2013, 230, 631-638.	1.5	14
130	Effects of pramipexole on the processing of rewarding and aversive taste stimuli. Psychopharmacology, 2013, 228, 283-290.	1.5	19
131	The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. Molecular Psychiatry, 2013, 18, 512-520.	4.1	199
132	The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. Journal of Psychopharmacology, 2013, 27, 575-583.	2.0	90
133	Unedited <i>in vivo</i> detection and quantification of γâ€aminobutyric acid in the occipital cortex using shortâ€TE MRS at 3 T. NMR in Biomedicine, 2013, 26, 1353-1362.	1.6	75
134	Psychobiotics Highlight the Pathways to Happiness. Biological Psychiatry, 2013, 74, 708-709.	0.7	33
135	Beta adrenergic blockade reduces utilitarian judgement. Biological Psychology, 2013, 92, 323-328.	1.1	32
136	â€~It's the way that you look at it'—a cognitive neuropsychological account of SSRI action in depression. Philosophical Transactions of the Royal Society B: Biological Sciences, 2013, 368, 20120407.	1.8	140
137	Cardiovascular and metabolic risk profile in young people at familial risk of depression. British Journal of Psychiatry, 2013, 203, 18-23.	1.7	37
138	Effects of Short-Term Varenicline Administration on Emotional and Cognitive Processing in Healthy, Non-Smoking Adults: A Randomized, Double-Blind, Study. Neuropsychopharmacology, 2013, 38, 476-484.	2.8	34
139	Antidepressant treatment and emotional processing: can we dissociate the roles of serotonin and noradrenaline?. Journal of Psychopharmacology, 2013, 27, 719-731.	2.0	30
140	Drug information update: agomelatine. The Psychiatrist, 2013, 37, 356-358.	0.3	5
141	Amine Depletors. , 2013, , 1-4.		Ο
142	Serotonin â \in 100 words. British Journal of Psychiatry, 2013, 203, 23-23.	1.7	0
143	Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine. Journal of Psychopharmacology, 2012, 26, 1417-1423.	2.0	18
144	Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. Journal of Psychopharmacology, 2012, 26, 733-737.	2.0	66

#	Article	IF	CITATIONS
145	Severity of depression and response to antidepressants: GENPOD randomised controlled trial. British Journal of Psychiatry, 2012, 200, 130-136.	1.7	23
146	Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychological Medicine, 2012, 42, 2609-2617.	2.7	202
147	Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. Journal of Psychopharmacology, 2012, 26, 663-669.	2.0	6
148	Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. Journal of Psychopharmacology, 2012, 26, 125-132.	2.0	44
149	Negative ion treatment increases positive emotional processing in seasonal affective disorder. Psychological Medicine, 2012, 42, 1605-1612.	2.7	24
150	Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate. International Journal of Neuropsychopharmacology, 2012, 15, 1541-1546.	1.0	30
151	Using Attentional Bias Modification as a Cognitive Vaccine Against Depression. Biological Psychiatry, 2012, 72, 572-579.	0.7	162
152	Neural Processing of Reward and Punishment in Young People at Increased Familial Risk of Depression. Biological Psychiatry, 2012, 72, 588-594.	0.7	140
153	Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Molecular Psychiatry, 2012, 17, 1254-1260.	4.1	63
154	Propranolol reduces implicit negative racial bias. Psychopharmacology, 2012, 222, 419-424.	1.5	87
155	In response to "The effect of agomelatine on 5HT2C receptors in humans: a clinically relevant mechanism?―by Trevor Norman. Psychopharmacology, 2012, 221, 179-179.	1.5	0
156	Reply to Burchett, T.S. and Glenn, L.L. â€~Measurement validity of tests for implicit negative bias'. Psychopharmacology, 2012, 222, 723-724.	1.5	2
157	Serotonergic Activity Influences the Cognitive Appraisal of Close Intimate Relationships in Healthy Adults. Biological Psychiatry, 2011, 69, 720-725.	0.7	28
158	Serotonin and Dopamine Play Complementary Roles in Gambling to Recover Losses. Neuropsychopharmacology, 2011, 36, 402-410.	2.8	70
159	5-HT and depression: is the glass half-full?. Current Opinion in Pharmacology, 2011, 11, 45-51.	1.7	87
160	A cognitive neuropsychological model of antidepressant drug action. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1586-1592.	2.5	107
161	Constructionism. BMJ: British Medical Journal, 2011, 342, d3195-d3195.	2.4	0
162	Has psychopharmacology got a future?. British Journal of Psychiatry, 2011, 198, 333-335.	1.7	13

#	Article	IF	CITATIONS
163	Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. British Journal of Psychiatry, 2011, 198, 464-471.	1.7	55
164	SSRI administration reduces resting state functional connectivity in dorso-medial prefrontal cortex. Molecular Psychiatry, 2011, 16, 592-594.	4.1	100
165	Carriage of the S′ allele serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) may influence brain morphology. Molecular Psychiatry, 2011, 16, 471-471.	4.1	8
166	Imaging vulnerability for depression. Molecular Psychiatry, 2011, 16, 1067-1068.	4.1	12
167	Frontolimbic responses to emotional faces in young people at familial risk of depression. Journal of Affective Disorders, 2011, 130, 127-132.	2.0	56
168	Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology, 2011, 213, 555-562.	1.5	65
169	Does agomelatine block 5-HT2C receptors in humans?. Psychopharmacology, 2011, 213, 653-655.	1.5	14
170	Short-term NK1 receptor antagonism and emotional processing in healthy volunteers. Psychopharmacology, 2011, 215, 239-246.	1.5	18
171	Serotonin revisited. Psychopharmacology, 2011, 213, 167-169.	1.5	3
172	The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers. Psychopharmacology, 2011, 217, 271-278.	1.5	39
173	Efficient γâ€aminobutyric acid editing at 3T without macromolecule contamination: MEGAâ€5PECIAL. NMR in Biomedicine, 2011, 24, 1277-1285.	1.6	68
174	Efficacy markers in depression. Journal of Psychopharmacology, 2011, 25, 1148-1158.	2.0	103
175	Neural response to angry and disgusted facial expressions in bulimia nervosa. Psychological Medicine, 2011, 41, 2375-2384.	2.7	26
176	Elevated cortical glutamate in young people at increased familial risk of depression. International Journal of Neuropsychopharmacology, 2011, 14, 255-259.	1.0	29
177	Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. Journal of Psychopharmacology, 2011, 25, 1159-1167.	2.0	61
178	Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. International Journal of Neuropsychopharmacology, 2010, 13, 1103-1113.	1.0	74
179	Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology, 2010, 210, 419-428.	1.5	30
180	A single dose of mirtazapine modulates neural responses to emotional faces in healthy people. Psychopharmacology, 2010, 212, 625-634.	1.5	58

#	Article	IF	CITATIONS
181	5-HT1A receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-11C]WAY-100635. Journal of Affective Disorders, 2010, 123, 77-80.	2.0	32
182	Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review. Journal of Psychopharmacology, 2010, 24, 513-520.	2.0	61
183	Not fade away: the HPA axis and depression. Psychological Medicine, 2010, 40, 1-4.	2.7	167
184	Increased neural response to fear in patients recovered from depression: a 3T functional magnetic resonance imaging study. Psychological Medicine, 2010, 40, 425-432.	2.7	62
185	Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers. Journal of Psychopharmacology, 2010, 24, 1217-1221.	2.0	18
186	Drs. Harmer, Goodwin, and Cowen Reply. American Journal of Psychiatry, 2010, 167, 599-600.	4.0	0
187	A Functional Magnetic Resonance Imaging Study of Verbal Working Memory in Young People at Increased Familial Risk of Depression. Biological Psychiatry, 2010, 67, 471-477.	0.7	40
188	Diminished Neural Processing of Aversive and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment. Biological Psychiatry, 2010, 67, 439-445.	0.7	282
189	Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. NeuroImage, 2010, 52, 50-54.	2.1	83
190	Antipsychotic-Induced Movement Disorders. , 2010, , 115-115.		0
191	Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses. NeuroImage, 2010, 50, 984-993.	2.1	21
192	Area Under the Curve. , 2010, , 151-151.		1
193	NK ₁ receptor antagonism and emotional processing in healthy volunteers. Journal of Psychopharmacology, 2010, 24, 481-487.	2.0	26
194	Memory impairment in young women at increased risk of depression: influence of cortisol and 5-HTT genotype. Psychological Medicine, 2009, 39, 757-762.	2.7	35
195	Research Letter: High-density negative ion treatment increases positive affective memory. Psychological Medicine, 2009, 39, 1930-1932.	2.7	14
196	NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers. International Journal of Neuropsychopharmacology, 2009, 12, 1261.	1.0	27
197	Brain serotonin transporter binding in former users of MDMA (â€~ecstasy'). British Journal of Psychiatry, 2009, 194, 355-359.	1.7	45
198	Negative Self-Beliefs in Relation to Eating Disorder and Depressive Symptoms: Different Themes Are Characteristic of the Two Sets of Symptoms in Those With Eating Disorders and/or Depression. Journal of Cognitive Psychotherapy, 2009, 23, 147-159.	0.2	17

#	Article	IF	CITATIONS
199	Effect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients. American Journal of Psychiatry, 2009, 166, 1178-1184.	4.0	408
200	Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. British Journal of Psychiatry, 2009, 195, 102-108.	1.7	451
201	Commentary on STAR*D: a summary and UK perspective. Journal of Psychopharmacology, 2009, 23, 618-619.	2.0	1
202	Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients. Journal of Affective Disorders, 2009, 119, 186-189.	2.0	37
203	Early effects of mirtazapine on emotional processing. Psychopharmacology, 2009, 203, 685-691.	1.5	67
204	Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology, 2009, 205, 85-91.	1.5	61
205	Neural representation of reward in recovered depressed patients. Psychopharmacology, 2009, 205, 667-677.	1.5	226
206	Short-term antidepressant treatment modulates amygdala response to happy faces. Psychopharmacology, 2009, 206, 197-204.	1.5	96
207	Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology, 2009, 207, 133-142.	1.5	47
208	Effect of a single dose of citalopram on amygdala response to emotional faces. British Journal of Psychiatry, 2009, 194, 535-540.	1.7	218
209	The Role of Serotonin in Nonnormative Risky Choice: The Effects of Tryptophan Supplements on the "Reflection Effect―in Healthy Adult Volunteers. Journal of Cognitive Neuroscience, 2009, 21, 1709-1719.	1.1	58
210	Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. Journal of Psychopharmacology, 2009, 23, 241-248.	2.0	200
211	Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. International Journal of Neuropsychopharmacology, 2009, 12, 169.	1.0	75
212	A big tent?. Psychiatric Bulletin, 2009, 33, 395-395.	0.3	1
213	Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers. Psychopharmacology, 2008, 199, 495-502.	1.5	61
214	Direct effects of diazepam on emotional processing in healthy volunteers. Psychopharmacology, 2008, 199, 503-513.	1.5	84
215	GENetic and clinical Predictors Of treatment response in Depression: the GenPod randomised trial protocol. Trials, 2008, 9, 29.	0.7	23
216	Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹ C]DASB in Healthy Controls. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1478-1490.	2.4	89

#	Article	IF	CITATIONS
217	The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study. Molecular Psychiatry, 2008, 13, 1011-1020.	4.1	62
218	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology, 2008, 22, 343-396.	2.0	437
219	Serotonin and depression: pathophysiological mechanism or marketing myth?. Trends in Pharmacological Sciences, 2008, 29, 433-436.	4.0	167
220	Emotional face processing in women with high and low levels of eating disorder related symptoms. Eating Behaviors, 2008, 9, 389-397.	1.1	31
221	Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. Journal of Psychopharmacology, 2008, 22, 473-476.	2.0	46
222	â€~It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychological Medicine, 2008, 38, 307-313.	2.7	117
223	Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. International Journal of Neuropsychopharmacology, 2008, 11, 255-60.	1.0	140
224	Wake-up call for British psychiatry. British Journal of Psychiatry, 2008, 193, 6-9.	1.7	183
225	Affective modulation of anterior cingulate cortex in young people at increased familial risk of depression. British Journal of Psychiatry, 2008, 192, 356-361.	1.7	48
226	Human 5-HT Transporter Availability Predicts Amygdala Reactivity <i>In Vivo</i> . Journal of Neuroscience, 2007, 27, 9233-9237.	1.7	86
227	5-HTT Binding in Recovered Depressed Patients and Healthy Volunteers: A Positron Emission Tomography Study With [¹¹ C]DASB. American Journal of Psychiatry, 2007, 164, 1858-1865.	4.0	66
228	Increased Waking Salivary Cortisol Levels in Young People at Familial Risk of Depression. American Journal of Psychiatry, 2007, 164, 617-621.	4.0	169
229	Effects of acute tyrosine depletion on subjective craving and selective processing of smoking-related cues in abstinent cigarette smokers. Journal of Psychopharmacology, 2007, 21, 805-814.	2.0	22
230	Effects of α-lactalbumin on emotional processing in healthy women. Journal of Psychopharmacology, 2007, 21, 519-524.	2.0	27
231	Short-term antidepressant treatment and facial processing. British Journal of Psychiatry, 2007, 190, 531-532.	1.7	99
232	Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations. British Journal of Psychiatry, 2007, 191, 282-284.	1.7	24
233	Emotional bias and waking salivary cortisol in relatives of patients with major depression. Psychological Medicine, 2007, 37, 403.	2.7	45
234	Single dose antidepressant administration modulates the neural processing of self-referent personality trait words. NeuroImage, 2007, 37, 904-911.	2.1	45

#	Article	IF	CITATIONS
235	A single dose of citalopram increases fear recognition in healthy subjects. Journal of Psychopharmacology, 2007, 21, 684-690.	2.0	214
236	Reduction in Occipital Cortex γ-Aminobutyric Acid Concentrations in Medication-Free Recovered Unipolar Depressed and Bipolar Subjects. Biological Psychiatry, 2007, 61, 806-812.	0.7	274
237	Reply to Low-Dose Tryptophan Depletion. Biological Psychiatry, 2007, 62, 543-544.	0.7	0
238	Validation of a Tracer Kinetic Model for the Quantification of 5-HT2A Receptors in Human Brain with [11C]MDL 100,907. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 161-172.	2.4	46
239	Impaired emotional categorisation in young people at increased familial risk of depression. Neuropsychologia, 2007, 45, 2975-2980.	0.7	43
240	Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues. Biological Psychiatry, 2006, 59, 816-820.	0.7	411
241	Lack of Effect of Chromium Supplementation on Mental State and Body Weight in People With Schizophrenia. Journal of Clinical Psychopharmacology, 2006, 26, 544-545.	0.7	4
242	5HT3 antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology, 2006, 186, 18-24.	1.5	51
243	Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers. Psychopharmacology, 2006, 187, 121-130.	1.5	76
244	Tryptophan depletion does not lower brain GABA levels in healthy volunteers. Psychopharmacology, 2006, 187, 131-132.	1.5	3
245	Pharmacology of drugs used in the treatment of mood disorders. Psychiatry (Abingdon, England), 2006, 5, 162-166.	0.2	4
246	Increased 5-HT _{2A} Receptor Binding in Euthymic, Medication-Free Patients Recovered From Depression: A Positron Emission Study With [¹¹ C]MDL 100,907. American Journal of Psychiatry, 2006, 163, 1580-1587.	4.0	170
247	Effect of Acute Tyrosine Depletion in Using a Branched Chain Amino-Acid Mixture on Dopamine Neurotransmission in the Rat Brain. Neuropsychopharmacology, 2006, 31, 310-317.	2.8	17
248	Neurobiology of Depression. , 2005, , 189-210.		0
249	The effects of a branched chain amino acid mixture supplemented with tryptophan on biochemical indices of neurotransmitter function and decision-making. Psychopharmacology, 2005, 179, 761-768.	1.5	41
250	Increased salivary cortisol after waking in depression. Psychopharmacology, 2005, 182, 54-57.	1.5	249
251	New drugs, old problems: Revisiting… Pharmacological management of treatment-resistant depression. Advances in Psychiatric Treatment, 2005, 11, 19-27.	0.6	21
252	Lack of Effect of Tyrosine Depletion on Mood in Recovered Depressed Women. Neuropsychopharmacology, 2005, 30, 786-791.	2.8	24

#	Article	IF	CITATIONS
253	Fluoxetine improves minor depressive disorders. Evidence-Based Mental Health, 2005, 8, 36-36.	2.2	0
254	Enhanced Early Morning Salivary Cortisol in Neuroticism. American Journal of Psychiatry, 2005, 162, 807-809.	4.0	134
255	Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biological Psychiatry, 2005, 57, 517-524.	0.7	149
256	Olanzapine Increases Slow Wave Sleep and Sleep Continuity in SSRI-Resistant Depressed Patients. Journal of Clinical Psychiatry, 2005, 66, 450-454.	1.1	63
25 7	5-HT1A receptor density and defensive personality - interaction of neurochemistry, personality and depression explored with [11C]WAY 100635 PET. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S376-S376.	2.4	0
258	The Creation of Psychopharmacology. By D. Healy. (Pp. 416; £27.50.) Harvard University Press: London. 2003 Psychological Medicine, 2004, 34, 173-175.	2.7	0
259	Increased Positive Versus Negative Affective Perception and Memory in Healthy Volunteers Following Selective Serotonin and Norepinephrine Reuptake Inhibition. American Journal of Psychiatry, 2004, 161, 1256-1263.	4.0	501
260	Preferential 5-HT1A Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression?. Neuropsychopharmacology, 2004, 29, 1688-1698.	2.8	33
261	Increased Brain GABA Concentrations Following Acute Administration of a Selective Serotonin Reuptake Inhibitor. American Journal of Psychiatry, 2004, 161, 368-370.	4.0	194
262	Methamphetamine Activates Reward Circuitry in Drug NaÃ ⁻ ve Human Subjects. Neuropsychopharmacology, 2004, 29, 1715-1722.	2.8	140
263	Comparison of the Effects of Citalopram and Escitalopram on 5-Ht-Mediated Neuroendocrine Responses. Neuropsychopharmacology, 2004, 29, 1699-1703.	2.8	40
264	Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Molecular Psychiatry, 2004, 9, 386-392.	4.1	231
265	Fos immunocytochemical studies on the neuroanatomical sites of action of acute tyrosine depletion in the rat brain. Psychopharmacology, 2004, 171, 435-440.	1.5	15
266	Tyrosine depletion does not cause depressive relapse in antidepressant-treated patients. Psychopharmacology, 2004, 175, 124-6.	1.5	10
267	Tyrosine-free amino acid mixture attenuates amphetamine-induced displacement of [11C]raclopride in striatum in vivo: A rat PET study. Synapse, 2004, 51, 151-157.	0.6	15
268	Normalization of Enhanced Fear Recognition by Acute SSRI Treatment in Subjects With a Previous History of Depression. American Journal of Psychiatry, 2004, 161, 166-168.	4.0	168
269	Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacology, 2003, 167, 411-417.	1.5	148
270	Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology, 2003, 167, 112-114.	1.5	27

#	Article	IF	CITATIONS
271	Acute administration of nutritionally sourced tryptophan increases fear recognition. Psychopharmacology, 2003, 169, 104-107.	1.5	103
272	Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet, The, 2003, 361, 799-808.	6.3	1,408
273	Lack of effect of a single dose of hydrocortisone on serotonin1A receptors in recovered depressed patients measured by positron emission tomography with [11C]WAY-100635. Biological Psychiatry, 2003, 54, 890-895.	0.7	20
274	Impairments in working memory associated with naturalistic dieting in women: no relationship between task performance and urinary 5-HIAA levels. Appetite, 2003, 40, 145-153.	1.8	38
275	Acute Reboxetine Administration Increases Plasma and Salivary Cortisol. Journal of Psychopharmacology, 2003, 17, 273-275.	2.0	15
276	Antidepressants and Emotional Processing. Neuropsychopharmacology, 2003, 28, 1384-1385.	2.8	5
277	Acute SSRI Administration Affects the Processing of Social Cues in Healthy Volunteers. Neuropsychopharmacology, 2003, 28, 148-152.	2.8	381
278	Reduction of Brain Dopamine Concentration With Dietary Tyrosine Plus Phenylalanine Depletion: An [11C]Raclopride PET Study. American Journal of Psychiatry, 2003, 160, 1887-1889.	4.0	104
279	GABA and mood disorders. Psychological Medicine, 2003, 33, 387-393.	2.7	36
280	The effect of a nutritional source of tryptophan on dieting-induced changes in brain 5-HT function. Psychological Medicine, 2003, 33, 1381-1386.	2.7	22
281	Increase in Concentration of Waking Salivary Cortisol in Recovered Patients With Depression. American Journal of Psychiatry, 2003, 160, 1890-1891.	4.0	140
282	Effects of a branched-chain amino acid drink in mania. British Journal of Psychiatry, 2003, 182, 210-213.	1.7	73
283	Toward a Neuropsychological Theory of Antidepressant Drug Action: Increase in Positive Emotional Bias After Potentiation of Norepinephrine Activity. American Journal of Psychiatry, 2003, 160, 990-992.	4.0	241
284	Risperidone Augmentation Decreases Rapid Eye Movement Sleep and Decreases Wake in Treatment-Resistant Depressed Patients. Journal of Clinical Psychiatry, 2003, 64, 192-196.	1.1	45
285	State and trait abnormalities in serotonin function in major depression. British Journal of Psychiatry, 2002, 180, 24-28.	1.7	106
286	Cortisol, serotonin and depression: All stressed out?. British Journal of Psychiatry, 2002, 180, 99-100.	1.7	117
287	Cerebellar responses during anticipation of noxious stimuli in subjects recovered from depression. British Journal of Psychiatry, 2002, 181, 411-415.	1.7	57
288	Mood, eating behaviour and attention. Psychological Medicine, 2002, 32, 469-481.	2.7	19

#	Article	IF	CITATIONS
289	Antidepressant drugs. Side Effects of Drugs Annual, 2002, 25, 13-20.	0.6	0
290	A Database of [11C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables. NeuroImage, 2002, 15, 620-632.	2.1	133
291	Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients. Journal of Affective Disorders, 2002, 72, 249-255.	2.0	17
292	Predictors of Mood Response to Acute Tryptophan Depletion A Reanalysis. Neuropsychopharmacology, 2002, 27, 852-861.	2.8	161
293	Chromium treatment decreases the sensitivity of 5-HT 2A receptors. Psychopharmacology, 2002, 159, 432-436.	1.5	57
294	Effect of branch chain amino acids supplemented with tryptophan on tyrosine availability and plasma prolactin. Psychopharmacology, 2002, 159, 222-223.	1.5	8
295	A dose-finding study on the effects of branch chain amino acids on surrogate markers of brain dopamine function. Psychopharmacology, 2002, 160, 192-197.	1.5	63
296	The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology, 2002, 163, 42-53.	1.5	219
297	Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology, 2002, 163, 118-120.	1.5	45
298	Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology, 2002, 163, 106-110.	1.5	96
299	Decreased sensitivity of 5-HT1D receptors in melancholic depression. British Journal of Psychiatry, 2001, 178, 454-457.	1.7	27
300	Decreased tryptophan availability but normal post-synaptic 5-HT2c receptor sensitivity in chronic fatigue syndrome. Psychological Medicine, 2001, 31, 585-591.	2.7	21
301	Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low. American Journal of Psychiatry, 2001, 158, 2080-2082.	4.0	80
302	Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. British Journal of Psychiatry, 2001, 179, 356-360.	1.7	133
303	Allelic variation in the 5-HT 2C receptor (HT2RC) and the increase in slow wave sleep produced by olanzapine. Psychopharmacology, 2001, 153, 271-272.	1.5	19
304	Tyrosine depletion attenuates dopamine function in healthy volunteers. Psychopharmacology, 2001, 154, 105-111.	1.5	147
305	Administration of the beta-adrenoceptor blocker propranolol impairs the processing of facial expressions of sadness. Psychopharmacology, 2001, 154, 383-389.	1.5	62
306	Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology, 2001, 155, 323-326.	1.5	77

#	Article	IF	CITATIONS
307	Tyrosine depletion attenuates the behavioural stimulant effects of amphetamine and cocaine in rats. European Journal of Pharmacology, 2001, 424, 115-119.	1.7	22
308	Effect of a Low Tryptophan Diet on the Prolactin Responses to the 5-HT2A Agonist DOI in the Rat. Pharmacopsychiatry, 2001, 34, 147-149.	1.7	6
309	The Effect of Li 1370, Extract of Ginkgo biloba, on REM Sleep in Humans. Pharmacopsychiatry, 2001, 34, 155-157.	1.7	3
310	Neuroendocrine markers of depression and antidepressant drug action. , 2001, , 95-107.		2
311	Modelling a loss event: effect of imagined bereavement on the hypothalamic–pituitary–adrenal axis. Psychological Medicine, 2000, 30, 219-223.	2.7	17
312	β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro Implications for Antidepressant Therapy. Neuropsychopharmacology, 2000, 23, 285-293.	2.8	70
313	Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology, 2000, 150, 120-122.	1.5	80
314	Repetitive transcranial magnetic stimulation to right prefrontal cortex does not modulate the psychostimulant effects of amphetamine. International Journal of Neuropsychopharmacology, 2000, 3, 297-302.	1.0	6
315	Brain Serotonin1A Receptor Binding Measured by Positron Emission Tomography With [11C]WAY-100635. Archives of General Psychiatry, 2000, 57, 174.	13.8	597
316	Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo. Biological Psychiatry, 2000, 47, 468-470.	0.7	129
317	Psychopharmacology of 5-HT1A receptors. Nuclear Medicine and Biology, 2000, 27, 437-439.	0.3	45
318	Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY-100635. Nuclear Medicine and Biology, 2000, 27, 509-513.	0.3	63
319	Acute effects of LI 160 (extract of Hypericum perforatum, St John's wort) and two of its constituents on neuroendocrine responses in the rat. Journal of Psychopharmacology, 2000, 14, 360-363.	2.0	16
320	Impaired regulation of brain serotonin function during dieting in women recovered from depression. British Journal of Psychiatry, 2000, 176, 72-75.	1.7	20
321	Effect of a long-term low tryptophan diet on the prolactin responses to the 5-HT1A and 5-HT2C agonists, 8-OH-DPAT and mCPP in the male rat. Journal of Psychopharmacology, 1999, 13, 58-63.	2.0	24
322	Attenuation of some subjective effects of amphetamine following tyrosine depletion. Journal of Psychopharmacology, 1999, 13, 144-147.	2.0	52
323	Effects of (â^')-tertatolol, (â^')-penbutolol and (±)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. British Journal of Pharmacology, 1999, 127, 145-152.	2.7	48
324	Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release. Psychopharmacology, 1999, 141, 182-188.	1.5	142

#	Article	IF	CITATIONS
325	Allelic variation in the 5-HT 2C receptor (HTR2C) and functional responses to the 5-HT 2C receptor agonist, m -chlorophenylpiperazine. Psychopharmacology, 1999, 144, 306-307.	1.5	15
326	Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT 1D receptors?. Psychopharmacology, 1999, 145, 223-226.	1.5	18
327	The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology, 1999, 145, 260-266.	1.5	218
328	Covariation of Activity in Habenula and Dorsal Raphé Nuclei Following Tryptophan Depletion. NeuroImage, 1999, 10, 163-172.	2.1	239
329	Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biological Psychiatry, 1999, 46, 581-584.	0.7	74
330	Symptomatic Relapse in Bulimia Nervosa Following Acute Tryptophan Depletion. Archives of General Psychiatry, 1999, 56, 171.	13.8	83
331	Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion. British Journal of Psychiatry, 1999, 174, 525-529.	1.7	124
332	Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo. British Journal of Pharmacology, 1998, 124, 206-212.	2.7	71
333	Lack of effect of hydrocortisone treatment on d -fenfluramine-mediated prolactin release. Psychopharmacology, 1998, 136, 198-200.	1.5	11
334	Antidepressant-like effect of Hypericum perforatum (St John's wort) on the sleep polysomnogram. Psychopharmacology, 1998, 139, 286-287.	1.5	34
335	Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT 2 receptors. Psychopharmacology, 1998, 140, 120-122.	1.5	15
336	Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia). Biological Psychiatry, 1998, 43, 236-237.	0.7	54
337	Effect of venlafaxine on pineal melatonin and noradrenaline in the male rat. Journal of Psychopharmacology, 1998, 12, 371-374.	2.0	12
338	Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment. British Journal of Psychiatry, 1998, 172, 243-249.	1.7	126
339	Probing the Function of 5-HT1B/1D Receptors in Psychiatric Patients. CNS Spectrums, 1998, 3, 40-45.	0.7	3
340	Assessment and treatment of insomnia (including a case control study of patients with Primary) Tj ETQq0 0 0 rgE	BT 10verloo	ck 10 Tf 50 1

341	Intravenous administration of haloperidol to healthy volunteers: lack of subjective effects but clear objective effects. Journal of Psychopharmacology, 1997, 11, 247-252.	2.0	14
342	Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. Journal of Psychopharmacology, 1997, 11, 345-348.	2.0	69

#	Article	IF	CITATIONS
343	Relapse of depression after rapid depletion of tryptophan. Lancet, The, 1997, 349, 915-919.	6.3	374
344	Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology, 1997, 129, 179-182.	1.5	47
345	Effect of paroxetine and nefazodone on 5-HT 1A receptor sensitivity. Psychopharmacology, 1997, 132, 296-302.	1.5	54
346	Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology, 1997, 133, 262-268.	1.5	72
347	SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology, 1997, 133, 305-308.	1.5	40
348	5-HT 2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology, 1997, 133, 309-312.	1.5	149
349	Brain serotonin (5-HT) neuroendocrine function in patients taking cholesterol-lowering drugs. Biological Psychiatry, 1996, 39, 100-106.	0.7	25
350	Schizotypy and height: reduced height in high-schizotypal healthy men. Personality and Individual Differences, 1996, 21, 823-825.	1.6	2
351	Antipsychotic drug effects in a model of schizophrenic attentional disorder: A randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biological Psychiatry, 1996, 40, 1135-1143.	0.7	63
352	Increased prolactin response to buspirone in chronic fatigue syndrome. Journal of Affective Disorders, 1996, 41, 71-76.	2.0	51
353	Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology, 1996, 126, 179-181.	1.5	85
354	The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology, 1996, 126, 50-54.	1.5	192
355	Paroxetine treatment and the prolactin response to sumatriptan. Psychopharmacology, 1996, 124, 377-379.	1.5	22
356	Effect of castration and castration with hormone replacement on the plasma prolactin responses to neuroendocrine challenge with i.v. mCPP in the male rat following a low tryptophan diet. Journal of Psychopharmacology, 1996, 10, 250-253.	2.0	6
357	Use of a dietary manipulation to deplete plasma tyrosine and phenylalanine in healthy subjects. Journal of Psychopharmacology, 1996, 10, 231-234.	2.0	54
358	Biochemical and behavioural effects of acute tryptophan depletion in abstinent bulimic subjects: a pilot study. Psychological Medicine, 1995, 25, 995-1001.	2.7	34
359	Hypophagic, endocrine and subjective responses tom-chlorophenylpiperazine in healthy men and women. Human Psychopharmacology, 1995, 10, 385-391.	0.7	34
360	Differential effects of clonidine, haloperidol, diazepam and tryptophan depletion on focused attention and attentional search. Psychopharmacology, 1995, 121, 222-230.	1.5	87

#	Article	IF	CITATIONS
361	Effect of pindolol on the prolactin response tod-denfluramine. Psychopharmacology, 1995, 118, 471-474.	1.5	39
362	Melatonin phase advances circadian rhythm. Psychopharmacology, 1995, 121, 503-505.	1.5	20
363	The effects of a low tryptophan diet on brain 5 -HT metabolism and 5-HT-mediated neuroendocrine responses in the male rat. Journal of Psychopharmacology, 1995, 9, 336-341.	2.0	19
364	Menstrual cycle effects on the action of buspirone on food intake in healthy female volunteers. Journal of Psychopharmacology, 1995, 9, 307-312.	2.0	1
365	Effect of pharmacologic treatments on the sleep of depressed patients. Biological Psychiatry, 1995, 37, 85-98.	0.7	266
366	Dieting decreases plasma tryptophan and increases the prolactin response to d-fenfluramine in women but not men. Journal of Affective Disorders, 1995, 33, 89-97.	2.0	58
367	5-HT 2C receptor sensitivity during treatment with selective serotonin re-uptake inhibitors. Journal of Psychopharmacology, 1994, 8, 168-170.	2.0	2
368	Effect of acute tryptophan depletion on mood and appetite in healthy female volunteers. Journal of Psychopharmacology, 1994, 8, 8-13.	2.0	46
369	Depression in the elderly. Journal of Psychopharmacology, 1994, 8, 68-69.	2.0	0
370	m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology, 1994, 116, 120-122.	1.5	80
371	Neuroendocrine effects of sumatriptan. Psychopharmacology, 1994, 113, 561-564.	1.5	26
372	p-Chloroamphetamine (PCA), 3,4-methylenedioxymethamphetamine (MDMA) andd-fenfluramine pretreatment attenuatesd-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology, 1994, 116, 508-514.	1.5	57
373	The effect of tryptophan on brain 5-HT function: A review. Human Psychopharmacology, 1994, 9, 371-376.	0.7	13
374	The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. Biological Psychiatry, 1994, 36, 309-316.	0.7	30
375	Slow wave sleep in humans: Role of 5-HT2A and 5-HT2C receptors. Neuropharmacology, 1994, 33, 467-471.	2.0	106
376	Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology, 1994, 33, 575-588.	2.0	291
377	Neuroendocrine responses to intravenous L-tryptophan in obsessive compulsive disorder. Journal of Affective Disorders, 1994, 32, 97-104.	2.0	13
378	Effects of hydrocortisone on brain 5-HT function and sleep. Journal of Affective Disorders, 1994, 32, 139-146.	2.0	45

#	Article	IF	CITATIONS
379	Antidepressant drugs. Side Effects of Drugs Annual, 1994, 18, 14-24.	0.6	0
380	5HT-3 receptor blockade in nicotine withdrawal: Study with BRL 46470A. Human Psychopharmacology, 1993, 8, 345-349.	0.7	1
381	Alcohol-induced reinforcement: Dopamine and 5-HT3 receptor interactions in animals and humans. Drug Development Research, 1993, 30, 153-169.	1.4	25
382	Ritanserin attenuates anorectic, endocrine and thermic responses tod-fenfluramine in human volunteers. Psychopharmacology, 1993, 112, 461-466.	1.5	145
383	Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology, 1993, 112, 142-144.	1.5	94
384	Effect of lofepramine on 5-HT function and sleep. Journal of Affective Disorders, 1993, 29, 63-72.	2.0	8
385	Neuroendocrine probes for 5-HT receptor subtypes. European Neuropsychopharmacology, 1993, 3, 306-308.	0.3	1
386	Effect of lithium on the prolactin response to d-fenfiuramine in healthy subjects. Biological Psychiatry, 1993, 33, 801-805.	0.7	11
387	meta-Chlorophenylpiperazine decreases slow-wave sleep in humans. Biological Psychiatry, 1993, 33, 49-51.	0.7	27
388	Neuroendocrine and temperature effects of nefazodone in healthy volunteers. Biological Psychiatry, 1993, 33, 115-119.	0.7	15
389	Low Serum Cholesterol and Suicide. British Journal of Psychiatry, 1993, 162, 818-825.	1.7	67
390	Antidepressant drugs. Side Effects of Drugs Annual, 1993, 17, 16-25.	0.6	0
391	The effect of the dopamine agonist, apomorphine, on regional cerebral blood flow in normal volunteers. Psychological Medicine, 1993, 23, 605-613.	2.7	52
392	Make-Believe in Psychiatry or the Perils of Progress. By Herman M. van Praag. New York: Brunner/Mazel Publishers. 1992. 320 pp. US \$39.95 British Journal of Psychiatry, 1993, 163, 420-421.	1.7	0
393	Commentary on 'The management of treatment-resistant affective disorder: clinical perspectives'. Journal of Psychopharmacology, 1992, 6, 158-159.	2.0	Ο
394	Effect of oestradiol treatment on 5-HT and dopamine-mediated neuroendocrine responses. Journal of Psychopharmacology, 1992, 6, 483-488.	2.0	9
395	Neuroendocrine challenge tests: Assessment of 5-HT function in anxiety and depression. Molecular Aspects of Medicine, 1992, 13, 205-220.	2.7	56
396	Sleep and 5-HT2 receptor sensitivity in recovered depressed patients. Journal of Affective Disorders, 1992, 24, 177-181.	2.0	7

#	Article	IF	CITATIONS
397	Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neuroscience Letters, 1992, 141, 106-110.	1.0	84
398	Effect of 5-hydroxy-l-tryptophan on the release of 5-HT in rat hypothalamus in vivo as measured by microdialysis. Neuropharmacology, 1992, 31, 9-14.	2.0	72
399	Nefazodone—A novel antidepressant— May increase REM sleep. Biological Psychiatry, 1992, 31, 1070-1073.	0.7	64
400	Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia. Biological Psychiatry, 1992, 32, 293-295.	0.7	18
401	Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: Preliminary open trial of the effects of acute and chronic idazoxan. Psychoneuroendocrinology, 1992, 17, 261-266.	1.3	7
402	Effect of estradiol implant on noradrenergic function and mood in menopausal subjects. Psychoneuroendocrinology, 1992, 17, 87-93.	1.3	86
403	Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet, The, 1992, 340, 1067-1068.	6.3	77
404	Selective 5-HT1A and 5-HT2 receptor-mediated adrenocorticotropin release in the rat: effect of repeated antidepressant treatments. European Journal of Pharmacology, 1992, 221, 27-33.	1.7	30
405	The Effect of Apomorphine and Buspirone on Regional Cerebral Blood Flow During the Performance of a Cognitive Task-Measuring Neuromodulatory Effects of Psychotropic Drugs in Man. European Journal of Neuroscience, 1992, 4, 1203-1212.	1.2	46
406	Does ondansetron attenuate amphetamine-induced behaviour in human volunteers?. Psychopharmacology, 1992, 107, 140-141.	1.5	21
407	Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man. Psychopharmacology, 1992, 108, 380-386.	1.5	27
408	Slow wave sleep and 5-HT2 receptor sensitivity in generalised anxiety disorder: a pilot study with ritanserin. Psychopharmacology, 1992, 108, 387-389.	1.5	29
409	Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology, 1992, 106, 428-432.	1.5	68
410	Evidence that the large neutral amino acidl-valine decreases electrically-evoked release of 5-HT in rat hippocampus in vivo. Psychopharmacology, 1992, 109, 251-253.	1.5	51
411	Altered in vitro adaptive responses of lymphocyte Na+,K+-ATPase in patients with manic depressive psychosis. Journal of Affective Disorders, 1991, 21, 199-206.	2.0	44
412	Blunted growth hormone and prolactin responses to L-tryptophan in depression; a state-dependent abnormality. Journal of Affective Disorders, 1991, 21, 213-218.	2.0	39
413	Prolactin response to the dopamine antagonist, metoclopramide, in depression. Biological Psychiatry, 1991, 30, 313-316.	0.7	8
414	Intravenous l-tryptophan and regional cerebral blood flow. Biological Psychiatry, 1991, 29, 508-509.	0.7	9

#	Article	IF	CITATIONS
415	Biological markers of depression. Psychological Medicine, 1991, 21, 831-836.	2.7	37
416	Calcium channel blockade and resistant bipolar depression. Irish Journal of Psychological Medicine, 1991, 8, 50-51.	0.7	6
417	Does metergoline selectively attenuate 5-HT mediated prolactin release?. Psychopharmacology, 1991, 105, 129-131.	1.5	11
418	Pindolol decreases prolactin and growth hormone responses to intravenousL-tryptophan. Psychopharmacology, 1991, 103, 140-142.	1.5	56
419	Lithium and 5-HT1A receptor sensitivity: a neuroendocrine study in healthy volunteers. Psychopharmacology, 1991, 105, 568-572.	1.5	16
420	Neuroendocrine and clinical responses in obsessive-compulsive disorder. Journal of Psychopharmacology, 1991, 5, 438-439.	2.0	1
421	Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. Journal of Psychopharmacology, 1991, 5, 396-403.	2.0	17
422	Neuroendocrine Effects of Azapirones. Journal of Clinical Psychopharmacology, 1990, 10, 21S-25S.	0.7	80
423	5-HT neuroendocrine responses during psychotropic drug treatment: an investigation of the effects of lithium. Journal of Neuroscience Methods, 1990, 34, 201-205.	1.3	9
424	The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology, 1990, 100, 498-503.	1.5	60
425	Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology, 1990, 101, 568-569.	1.5	64
426	Metergoline abolishes the prolactin response to buspirone. Psychopharmacology, 1990, 100, 283-284.	1.5	18
427	Peripubertal human breast development. The Anatomical Record, 1990, 226, 501-508.	2.3	39
428	Sleep Stability with Home Sleep Recording and Automatic Sleep Stage Analysis. Sleep, 1990, 13, 538-540.	0.6	21
429	Drug Treatment of Tricyclic Resistant Depression. International Review of Psychiatry, 1990, 2, 239-248.	1.4	6
430	Dieting reduces plasma tryptophan and alters brain 5-HT function in women. Psychological Medicine, 1990, 20, 785-791.	2.7	156
431	Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet, The, 1990, 335, 1484-1487.	6.3	118
432	Effect of amitriptyline on endocrine responses to intravenous L-trytophan. Psychiatry Research, 1990, 31, 201-208.	1.7	15

#	Article	IF	CITATIONS
433	Effects of MDL 73005EF on central pre- and postsynaptic 5-HT1A receptor function in the rat in vivo. European Journal of Pharmacology, 1990, 191, 391-400.	1.7	48
434	Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. European Journal of Pharmacology, 1990, 179, 103-109.	1.7	52
435	Slow wave sleep and 5-HT2 receptor sensitivity during maintenance tricyclic antidepressant treatment. Journal of Affective Disorders, 1990, 19, 273-277.	2.0	22
436	Decreased plasma tryptophan concentration in major depression: relationship to melancholia and weight loss. Journal of Affective Disorders, 1990, 20, 185-191.	2.0	42
437	L-tryptophan and the eosinophilia-myalgia syndrome. Psychiatric Bulletin, 1990, 14, 738-739.	0.3	0
438	Increased slow wave sleep with 5-HT2 receptor antagonists: detection by ambulatory EEG recording and automatic sleep stage analysis. Journal of Psychopharmacology, 1989, 3, 125-129.	2.0	23
439	Lithium increases slow wave sleep: possible mediation by brain 5-HT2 receptors?. Psychopharmacology, 1989, 98, 139-140.	1.5	58
440	Lithium increases 5-HT-mediated neuroendocrine responses in tricyclic resistant depression. Psychopharmacology, 1989, 99, 230-232.	1.5	37
441	Lithium increases 5-HT-mediated prolactin release. Psychopharmacology, 1989, 99, 276-281.	1.5	23
442	Effect of moderate weight loss on prolactin secretion in normal female volunteers. Psychiatry Research, 1989, 29, 161-167.	1.7	11
443	Decreased plasma tryptophan levels in major depression. Journal of Affective Disorders, 1989, 16, 27-31.	2.0	133
444	The effect of moderate weight loss on overnight growth hormone and cortisol secretion in healthy female volunteers. Journal of Affective Disorders, 1989, 16, 197-202.	2.0	11
445	Effects of carbamazepine on sleep in healthy volunteers. Biological Psychiatry, 1989, 26, 324-328.	0.7	65
446	Effect of idazoxan on evening melatonin plasma concentrations in healthy volunteers. Biological Psychiatry, 1989, 26, 412-416.	0.7	8
447	The effect of clonidine and bright light on plasma melatonin. Human Psychopharmacology, 1988, 3, 43-46.	0.7	5
448	The effects of dieting and weight loss upon the stimulation of thyrotropin (TSH) by thyrotropin-releasing hormone (TRH) and suppression of cortisol secretion by dexamethasone in men and women. Journal of Affective Disorders, 1988, 14, 137-144.	2.0	16
449	Recent views on the role of 5-hydroxytryptamine in depression. Current Opinion in Psychiatry, 1988, 1, 56-59.	3.1	12
450	Binding of tritiated yohimbine to platelets in women with maternity blues. Psychological Medicine, 1988, 18, 837-842.	2.7	15

#	Article	IF	CITATIONS
451	Evaluation of First Night Effect using Ambulatory Monitoring and Automatic Sleep Stage Analysis. Sleep, 1988, 11, 273-276.	0.6	107
452	Low tolerability of carbamazepine in psychiatric patients may restrict its clinical usefulness. Journal of Psychopharmacology, 1988, 2, 1-4.	2.0	23
453	The effect of metergoline on endocrine responses to L-tryptophan. Journal of Psychopharmacology, 1987, 1, 90-94.	2.0	22
454	The pineal and psychiatry: still fumbling in the dark?. Psychological Medicine, 1987, 17, 817-820.	2.7	6
455	Neuroendocrine Responses to Intravenous Tryptophan in Major Depression. Archives of General Psychiatry, 1987, 44, 958.	13.8	127
456	Psychotropic drugs and human 5-HT neuroendocrinology. Trends in Pharmacological Sciences, 1987, 8, 105-108.	4.0	32
457	Dieting and weight loss in volunteers increases the number of α2-adrenoceptors and 5-HT receptors on blood platelets without effect on [3H]imipramine binding. Journal of Affective Disorders, 1987, 12, 267-274.	2.0	25
458	Platelet 5-HT receptor binding during depressive illness and tricyclic antidepressant treatment. Journal of Affective Disorders, 1987, 13, 45-50.	2.0	72
459	Endocrine responses to tryptophan infusion in schizophrenic patients treated with neuroleptics. Psychoneuroendocrinology, 1987, 12, 193-202.	1.3	9
460	The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to l-tryptophan. Psychopharmacology, 1987, 93, 416-20.	1.5	72
461	Selective effect of lithium on cognitive performance in man. Psychopharmacology, 1987, 91, 109-111.	1.5	18
462	Anecdotal treatment in resistant depression. Human Psychopharmacology, 1987, 2, 135-136.	0.7	0
463	Monoamine function in anxiety and depression: Information from neuroendocrine challenge tests. Human Psychopharmacology, 1987, 2, 211-220.	0.7	16
464	Neuroendocrine Responses as a Probe into the Mechanisms of Action of Electroconvulsive Therapy. Annals of the New York Academy of Sciences, 1986, 462, 163-171.	1.8	4
465	Desipramine Treatment in Normal Subjects. Archives of General Psychiatry, 1986, 43, 61.	13.8	77
466	Personality and psychosis: use of the Standardized Assessment of Personality. Acta Psychiatrica Scandinavica, 1986, 73, 87-92.	2.2	39
467	Binding of yohimbine and imipramine to platelets in depressive illness. Psychological Medicine, 1986, 16, 765-773.	2.7	43
468	L-Tryptophan and prolactin release: Evidence for interaction between 5-HT1 and 5-HT2 receptors. Human Psychopharmacology, 1986, 1, 93-97.	0.7	78

#	Article	IF	CITATIONS
469	Clomipramine enhances prolactin and growth hormone responses to l-tryptophan. Psychopharmacology, 1986, 89, 131-3.	1.5	61
470	The effect of lithium on 5-HT-mediated neuroendocrine responses and platelet 5-HT receptors. Psychopharmacology, 1986, 90, 398-402.	1.5	71
471	The effect of diazepam on indices of 5-HT function in man. Pharmacology Biochemistry and Behavior, 1986, 24, 1491-1495.	1.3	14
472	Effects of the contraceptive pill on sedative responses to clonidine and apomorphine in normal women. Psychological Medicine, 1985, 15, 363-367.	2.7	14
473	Responses of prolactin and growth hormone to L-tryptophan infusion: Effects in normal subjects and schizophrenic patients receiving neuroleptics. Psychopharmacology, 1985, 86, 164-169.	1.5	76
474	Treatment with betaâ€adrenoceptor blockers reduces plasma melatonin concentration British Journal of Clinical Pharmacology, 1985, 19, 258-260.	1.1	59
475	Increased platelet membrane [3H]â€LSD binding in patients on chronic neuroleptic treatment British Journal of Clinical Pharmacology, 1985, 19, 453-457.	1.1	19
476	Plasma melatonin during desmethylimipramine treatment: evidence for changes in noradrenergic transmission British Journal of Clinical Pharmacology, 1985, 19, 799-805.	1.1	51
477	The pharmacokinetics of Lâ€ŧryptophan following its intravenous and oral administration British Journal of Clinical Pharmacology, 1985, 20, 317-321.	1.1	10
478	The benzodiazepine antagonist, Ro 15-1788 does not decrease ethanol withdrawal convulsions in rats. European Journal of Pharmacology, 1985, 107, 375-377.	1.7	18
479	The effect of amitriptyline treatment on the growth hormone response to apomorphine. Psychopharmacology, 1984, 83, 378-379.	1.5	6
480	Studies on the mechanisms by which clenbuterol, a β-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat. Neuropharmacology, 1983, 22, 739-749.	2.0	40
481	Comparison of the effects of chronic desmethylimipramine administration on α2- and β-adrenoceptors in different regions of rat brain. Neuroscience, 1983, 8, 161-164.	1.1	47
482	Atenolol reduces plasma melatonin concentration in man British Journal of Clinical Pharmacology, 1983, 15, 579-581.	1.1	80
483	The effect of chronic antidepressant administration on βâ€ a drenoceptor function of the rat pineal. British Journal of Pharmacology, 1983, 78, 89-96.	2.7	37
484	Further evidence for a relationship between changes in GABA concentration in rat brain and enhanced monoamine-mediated behavioural responses following repeated electroconvulsive shock. Neuropharmacology, 1982, 21, 981-984.	2.0	20
485	βâ€ADRENOCEPTOR AGONISTS ENHANCE 5â€HYDROXYTRYPTAMINEâ€MEDIATED BEHAVIOURAL RESPONSES. I Journal of Pharmacology, 1982, 76, 265-270.	British 2.7	57
486	ECT and the Growth Hormone Response to Apomorphine. British Journal of Psychiatry, 1982, 141, 213-213.	1.7	1

#	Article	IF	CITATIONS
487	Using Ro 15-1788 to investigate the benzodiazepine receptor in vivo: Studies on the anticonvulsant and sedative effect of melatonin and the convulsant effect of the benzodiazepine Ro 05-3663. Psychopharmacology, 1982, 78, 293-295.	1.5	37
488	Repeated administration of subconvulsant doses of GABA antagonist drugs. Psychopharmacology, 1982, 76, 84-87.	1.5	53
489	Repeated administration of subconvulsant doses of GABA antagonist drugs. Psychopharmacology, 1982, 76, 88-91.	1.5	6
490	Unusual interactions of benzodiazepine receptor antagonists. Nature, 1982, 295, 436-438.	13.7	292
491	Studies on the post-ictal rise in seizure threshold. European Journal of Pharmacology, 1981, 71, 287-295.	1.7	70
492	Ethyl β-carboline carboxylate lowers seizure threshold and antagonizes flurazepam-induced sedation in rats. Nature, 1981, 290, 54-55.	13.7	232
493	On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock. Neuropharmacology, 1980, 19, 1017-1023.	2.0	77
494	Repeated electroconvulsive shock does not increase the susceptibility of rats to a cage convulsant (Isopropylbicyclophosphate). Neuropharmacology, 1980, 19, 1025-1026.	2.0	3
495	Enhanced 5-hydroxytryptamine and dopamine-mediated behavioural responses following convulsions—II the effects of anaesthesia and current conditions on the appearance of enhanced responses following electroconvulsive shock. Neuropharmacology, 1980, 19, 901-906.	2.0	20
496	Pharmacotherapy of Suicidal Ideation and Behaviour. , 0, , 487-502.		11
497	Combination Antidepressant Therapy vs Monotherapy—Further Considerations. JAMA Psychiatry, 0, , .	6.0	1